Items Tagged ‘gm-csf’

November 12, 2014

Immune Booster Combined with Checkpoint Blocker Improves Survival in Metastatic Melanoma


(CancerConnect) Patients with metastatic melanoma who were treated with ipilimumab, an immune checkpoint blocker, survived 50 percent longer – a median 17.5 months vs. 12.7 months – if they simultaneously received an immune stimulant, according to a study led by Dana-Farber Cancer Institute scientists. Patients in the clinical trial who got the combined therapies also […]

View full entry

Tags: gm-csf, ipilimumab, Melanoma, News, Recurrent Melanoma, sargramostim, Stage IV Melanoma, Yervoy